CClinicalTrials.gg
CompletedNCT02970565Updated Feb 15, 2023

Family Nurture Intervention, A Group Model in Connecticut

An interventional study of Family Nurture Intervention and Nutrition and Play Intervention in Behavior Problem, Development Delay and Emotional Disturbance, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 24 Months to 54 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Columbia University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
24 Months to 54 Months
Sex
All
01

Study summary

The purpose of this current study is to investigate the efficacy of a group model of Family Nurture Intervention in ameliorating behavioral problems in preschool-aged children. The behavioral, neurobiological and clinical insights gained from this project may eventually lead to better treatment of emotional, behavioral and developmental disorders. The investigator hypothesizes that the children who are treated with Family Nurture Intervention (FNI), which incorporates interactive touch with vocal soothing, and family practice in comforting, will show increased emotional connection and mother child co-regulation with better results in the outcome measures in the short term and long term.

Read the detailed description

There are several early intervention programs that are available for children with emotional, behavioral and developmental disorders, ranging from behavioral treatment and sensory exposure therapy to pharmaceutical treatments. Although improvements in behavior have resulted from these interventions, they are limited in numerous ways. They are usually time-consuming, both for the child and the teacher or clinician providing the intervention. In order to see an effect of the intervention, most children must engage in the intervention procedure for several years. Moreover, the effects of most current intervention procedures are minimal to moderate. Pharmaceutical prescriptions are often accompanied by undesirable side effects that may modulate behavior, emotion, and physiological functions. The behavioral, neurobiological and clinical insights gained from this project may eventually lead to better treatment of emotional, behavioral and developmental disorders.

02

Conditions studied

  • Behavior Problem
  • Development Delay
  • Emotional Disturbance
  • Family Conflict

Keywords

  • Family Nurture Intervention
  • Martha G. Welch MD
  • Randomized Control Trial
  • Pre-school Intervention
  • Preschool Intervention
  • Multiple Family Group Intervention
  • Emotional Connection
  • Co-regulation
03

In context

Problem Behavior

517 studies on the registry are indexed under Problem Behavior; 92 are open to participants now.

This study's enrollment of 106 is above the median of 90 across 391 interventional studies indexed under Problem Behavior.

Browse Problem Behavior studies →

Lead sponsor

Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.

Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Months to 54 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Child is a singleton
  • Mother can speak in English or Spanish
  • Child is between the ages of 2 to 4 ½ years at date of enrollment
  • Mother is 18 years of age or older at the time of consent
  • Child demonstrates developmental deficit as measured by the SDQ (cutoff of 13 or more on the total score excluding the pro-social questions; OR 4 or less on the pro-social questions, which are reverse scored i.e. higher is better)
  • Child must reside with mother

Exclusion criteria

Exclusion Criteria:

  • The child has severe congenital anomalies or chromosomal anomalies including Downs syndrome and Cerebral Palsy
  • The child has a diagnosis of Autism
  • The child has severe motor or physical disability
  • Mother currently presents with psychosis or is currently taking antipsychotic medication
  • Current maternal drug and/or alcohol abuse
  • Mother has any current involvement with Child Protective Services (Department of Children and Families)
  • Mother is pregnant
  • Mother and/or infant has a medical condition or contagion that precludes intervention components
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Nutrition and Play Intervention

    Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.

    Behavioral: Nutrition and Play Intervention

  • Experimental
    Family Nurture Intervention

    Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.

    Behavioral: Family Nurture Intervention

Interventions

  • BehavioralFamily Nurture Intervention

    The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.

    Also known as: FNI

  • BehavioralNutrition and Play Intervention

    Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.

    Also known as: NPI

06

What researchers measure

Primary outcomes

  1. Change in Childhood Behavior Checklist (CBCL) Score

    The Childhood Behavior Checklist (CBCL) is a device by which parents or other individuals who know the child well rate a child's problem behaviors and competencies. This instrument can either be self-administered or administered through an interview. The CBCL can also be used to measure a child's change in behavior over time or following a treatment. The first section of this questionnaire consists of 20 competence items and the second section consists of 120 items on behavior or emotional problems.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Co-regulation of Vagal Tone

    Using ECG data obtained during each follow-up visit, the investigators will characterize various parameters of cardiac function and regulation including assessments of parasympathetic modulation of heart rate. Long term individual differences in attention and emotional regulation are correlated with these parameters. Heart rate and respiration obtained from analogue outputs from standard clinical monitors or from specially designed hardware utilized routinely in the studies of human infants. The digitized recordings of ECG and respiration will be processed using software designed specifically for displaying, marking, and analyzing data from these records.

    Time frame: Up to 12 months

  2. Change in Maternal Anxiety and Depressive Symptoms

    Mothers will complete various questionnaires measuring their mood and state.

    Time frame: Up to 12 months

  3. Changes in Welch Emotional Connection Scale

    This is a clinical tool to assess the emotional connectedness of a mother-child dyad. The aim of the WECS is to assess behaviors observed during mother-child interaction, and score these behavioral observations across four domains to better inform health professionals of a dyad's interventional need. This scale will be completed by study staff.

    Time frame: Up to 12 months

07

Study locations

1 site
  • Norwalk Housing Authority
    Cos Cob, Connecticut 06807, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02970565
Lead sponsor
Columbia University
Responsible party
Martha G Welch (Associate Professor of Psychiatry (in Pediatrics and Pathology and Cell Biology), Columbia University) — Principal investigator
First posted
Nov 22, 2016
Start date
Oct 2016
Primary completion
May 2019
Completion
May 2019
Last update
Feb 15, 2023

Study contacts

Martha G Welch, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion